The South America Anti-VEGF market is undergoing substantial growth, which is primarily due to the rising prevalence of retinal disorders, including diabetic retinopathy and age-related macular degeneration (AMD). The prevalence of these conditions is increasing as a result of the ageing population and the increasing prevalence of diabetes in countries such as Argentina and Brazil.
Furthermore, the healthcare infrastructure in South America is enhancing, with a rise in investments in ophthalmic care, which is resulting in higher rates of diagnosis and treatment. The availability of sophisticated therapies and medications is also a significant market driver, as a variety of anti-VEGF agents are now available, which has improved the treatment options available to patients. There are significant opportunities to be investigated as the market evolves, particularly in the expansion of treatment accessibility in rural and underserved regions.
A more proactive approach to seeking medical assistance may result from the increasing awareness of the significance of eye health among citizens. The market can be further expanded by increasing the number of patients pursuing Anti-VEGF treatments through public health initiatives that are designed to educate the population about retinal diseases. Pharmaceutical companies and healthcare providers have been collaborating more frequently in recent years to enhance patient outcomes and treatment protocols.
In the field of ophthalmology, there is a growing trend towards personalized medicine, as tailored therapies are gaining traction. Additionally, the landscape of anti-VEGF therapy in South America may be altered by the development of innovative drug delivery systems, including sustained release implants and nanotechnology-based treatments. In general, the region's market is dynamic and evolving, as evidenced by the convergence of these drivers and emergent trends.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The South America Anti-Vascular Endothelial Growth Factor (VEGF) Market Industry is primarily driven by the increasing prevalence of eye diseases such as diabetic retinopathy and age-related macular degeneration. According to the Pan American Health Organization, the rate of diabetes in South America has been steadily rising, with an estimated 16 million individuals affected in the region, leading to increased incidence of related complications such as diabetic retinopathy.This surge in eye diseases necessitates effective treatment options, including anti-VEGF therapies, thus fueling demand in the South America Anti-VEGF Market. Established pharmaceutical companies like Novartis and Roche, which focus extensively on R&D for innovative anti-VEGF treatments, play a significant role in addressing this growing need. Their involvement not only boosts treatment availability but also raises awareness about the importance of early diagnosis and intervention, further enhancing market growth potential.
Technological advancements in treatment modalities for eye diseases are another strong driver of the South America Anti-VEGF Market Industry. The integration of innovative drug delivery systems, such as sustained release formulations and ocular implants, has improved patient compliance and outcomes significantly. For instance, recent developments by companies like Alimera Sciences in sustained-release delivery systems provide a competitive edge in the market.Additionally, the Brazilian Health Regulatory Agency (ANVISA) has streamlined the approval process for new anti-VEGF therapies, encouraging more investments in Research and Development. The introduction of advanced treatment options not only expands the accessibility for patients across South America but also enhances the growth trajectory of the market.
The increasing proportion of the aging population in South America is a notable driver for the Anti-Vascular Endothelial Growth Factor (VEGF) Market Industry. With the World Health Organization projecting that the number of older adults (aged 60 years and above) in South America will surpass 85 million by 2050, the demand for effective treatments for age-related eye conditions is set to rise dramatically. This demographic transformation indicates a higher likelihood of chronic eye diseases, consequently escalating the need for anti-VEGF therapies.Organizations like the International Federation on Aging emphasize the importance of accessible healthcare solutions for this demographic, leading to partnerships with pharmaceutical firms to develop targeted therapies for age-related macular degeneration, thereby propelling market growth for anti-VEGF solutions in the region.
The South America Anti-VEGF Market segment, particularly focused on Product, is experiencing notable growth, driven by an increasing prevalence of retinal disorders and the growing aging population in the region. Anti-VEGF therapies play a crucial role in treating conditions such as age-related macular degeneration and diabetic retinopathy, highlighting their importance in ophthalmic care. Within this segment, Eylea has emerged as a leading treatment due to its effective long-term results and favorable dosing schedule, which has helped it capture a significant market share.
Lucentis remains a vital player as well, widely recognized for its efficacy in managing certain eye diseases, and is frequently used in clinical settings across various South American countries. Beovu, while newer in the market, is gaining traction due to its innovative formulation that promises improved outcomes for patients with serious retinal diseases. The overall dynamics in the South America Anti-VEGF Market are compelling, as factors like ongoing Research and Development efforts, advancements in drug formulations, and increased awareness about ocular health are shaping the landscape.Additionally, collaborations between pharmaceutical companies and healthcare providers are enhancing access to these therapies, ultimately supporting the market's expansion. Overall, the Product segment within the South America Anti-VEGF Market presents significant opportunities for stakeholders due to its essential role in addressing pressing healthcare needs in the region's population.
The South America Anti-VEGF Market within the Disease segment encompasses several critical conditions that necessitate targeted treatment, notably including Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, and Age-Related Macular Degeneration. Focused on addressing vision impairments caused by these diseases, the market experiences significant demand due to the rising prevalence of diabetes and the aging population in South America. Macular Edema often results from diabetes, highlighting the intersection of these health challenges and underscoring the need for effective anti-VEGF therapies.
Diabetic Retinopathy is a leading cause of blindness in working-age adults, making it a priority within healthcare systems in the region. Retinal Vein Occlusion also contributes significantly to vision loss, creating urgency for effective treatment solutions. Meanwhile, Age-Related Macular Degeneration continues to be a pressing concern as the population ages, creating a growing market for anti-VEGF drugs. Overall, the Disease segment within the South America Anti-VEGF Market reflects a landscape shaped by the increasing incidence of these conditions, driving innovation and therapeutic development aimed at improving patient outcomes and addressing significant public health challenges.
The South America Anti-VEGF Market exhibits a dynamic landscape, particularly driven by key countries like Brazil, Mexico, and Argentina. Brazil leads the market due to its substantial healthcare spending and a growing patient population suffering from retinal diseases, making it a focal point for anti-VEGF treatments. Mexico also presents significant opportunities, bolstered by increasing awareness and acceptance of advanced therapies among healthcare professionals and patients.
Argentina, while smaller in comparison, is experiencing a rise in government initiatives aimed at improving eye care services, which fuels the demand for anti-VEGF treatments.A diverse range of healthcare systems and varying levels of access to anti-VEGF therapies characterize the Rest of South America. Overall, the South America Anti-VEGF Market reflects a promising trajectory with increasing focus on improving healthcare infrastructure, expanding patient access, and addressing unmet medical needs across the region. Factors such as a rising geriatric population, increased prevalence of degenerative eye disorders, and advancements in pharmaceutical research play pivotal roles in shaping the market dynamics. With ongoing developments in healthcare policies and an emphasis on telemedicine, the region presents numerous growth opportunities for industry players.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The South America Anti-VEGF market has witnessed substantial growth due to the increasing prevalence of ocular diseases, particularly age-related macular degeneration and diabetic retinopathy. The competitive landscape is characterized by a mix of established companies and emerging players, all striving to capture market share through innovative product formulations, strategic partnerships, and extensive distribution networks. Key factors influencing competition include the introduction of biosimilars, advancements in research and development, and the growing emphasis on patient-centric solutions. Companies are also focusing on strengthening their presence in the market by expanding their product portfolios and enhancing accessibility to anti-VEGF therapies across diverse regions in South America.
Hikma Pharmaceuticals has established itself as a significant player in the South America Anti-VEGF market. With a robust portfolio that includes both generic and branded medications, the company is well-positioned to leverage its strengths in manufacturing and distribution within the region. Hikma's commitment to high-quality standards, combined with its diverse range of formulations, has allowed it to meet varying market demands effectively. The company's strategies to collaborate with healthcare professionals and engage in educational campaigns further enhance its visibility and acceptance in the region. By optimizing its supply chain and focusing on operational efficiencies, Hikma has managed to create a competitive edge that secures its position in the South American market.
Eisai has also made notable strides in the South America anti-VEGF market, particularly with its innovative product offerings that address significant unmet medical needs. The company's focus on research and development enables it to provide cutting-edge therapies that cater to the diverse patient demographics in the region. Eisai's strategic partnerships with local distributors have facilitated greater market penetration and accessibility for its key services and products. Through targeted marketing initiatives and educational programs, Eisai is able to build strong relationships with healthcare providers, enhancing its brand recognition. Recent mergers and acquisitions have further strengthened Eisai’s market presence, allowing it to expand its portfolio and usher in new technologies focused on improving patient outcomes in the South American anti-VEGF landscape.
The South America Anti-VEGF Market has recently seen significant developments, with companies like Novartis and Regeneron Pharmaceuticals actively expanding their market presence. In March 2023, Novartis unveiled robust results from clinical trials supporting the efficacy of their anti-VEGF treatments, which are expected to bolster their share in the region. On the competitive front, Alliances between Hikma Pharmaceuticals and local biotech firms have fostered advancements in product distribution, with multiple launches projected for the coming year.In terms of market dynamics, the growing prevalence of retinal diseases in South America is driving a surge in demand for anti-VEGF therapies. As of October 2023, Amgen and Pfizer reported significant growth in their market valuation as a result of increased investments in Research and Development and expanded access programs, positively impacting overall market health. The health authorities are also ramping up efforts to ensure better accessibility to anti-VEGF treatments, acknowledging the rising disease burden.No recent mergers or acquisitions involving the specified companies have been publicly disclosed in this sector. However, Santen Pharmaceutical's strategic partnerships with regional players hint at potential future consolidations.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.25(USD Billion) |
| MARKET SIZE 2024 | 1.3(USD Billion) |
| MARKET SIZE 2035 | 2.07(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.313% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Hikma Pharmaceuticals, Eisai, Regeneron Pharmaceuticals, Santen Pharmaceutical, Mylan, Amgen, Novartis, Pfizer, Genentech, Roche, Alcon, AbbVie, Orbis International, Bayer, Bausch Health |
| SEGMENTS COVERED | Product, Disease, Regional |
| KEY MARKET OPPORTUNITIES | Rising prevalence of ocular diseases, Increasing aging population, Expanding healthcare infrastructure, Growing adoption of biosimilars, Enhanced patient awareness and education |
| KEY MARKET DYNAMICS | rising prevalence of eye diseases, increasing geriatric population, advancements in drug delivery, growing healthcare expenditure, strong research and development activities |
| COUNTRIES COVERED | Brazil, Mexico, Argentina, Rest of South America |
Frequently Asked Questions (FAQ) :
The South America Anti-VEGF Market is expected to be valued at 1.3 billion USD in 2024.
By 2035, the market value of the South America Anti-VEGF Market is anticipated to reach 2.07 billion USD.
The expected compound annual growth rate (CAGR) for the South America Anti-VEGF Market from 2025 to 2035 is 4.313%.
Brazil is expected to hold the largest market share, valued at approximately 0.52 billion USD in 2024.
Eylea is projected to reach a market value of 0.88 billion USD by 2035 in the South America Anti-VEGF Market.
Major players include Novartis, Amgen, and Regeneron Pharmaceuticals, among others.
The market size for Mexico is expected to grow from 0.34 billion USD in 2024 to 0.52 billion USD by 2035.
The market value of Lucentis is forecasted to be 0.67 billion USD in 2035.
Growth drivers include increasing prevalence of retinal diseases and advancements in therapeutic options.
Beovu is expected to reach a market value of 0.52 billion USD by 2035 in the South America Anti-VEGF Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
